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Background: Pulmonary autografts offer many theoretical advantages. 
However, the operation is complex, may interfere with right ventricular and 
pulmonary outflow function, and requires a longer operative time than does 
the homograft operation. The effects of these potential disadvantages are 
unknown. Methods: To clarify these issues we randomized 70 patients 
undergoing aortic valve replacement to an aortic homograft group (group 
A = 37 patients; 53%; 34 male, 3 female) or a pulmonary autograft group 
(group B = 33 patients; 47%; 28 male, 5 female). Ages varied from 12 to 65 
years (mean 39 - 15 years) for group A and from 3 to 54 years (mean 29 - 
15 years) for group B (p = not significant). Eleven patients in group A 
(30%) and eight in group B (24%) had previous aortic valve surgery. All 
patients were operated on by the same surgeon. The mean cardiopulmonary 
bypass time was 113 - 29 minutes (range 66 to 175 minutes) for group A 
and 151 - 31 minutes (range 115 to 226 minutes) for group B (p < 0.002). 
Mean aortic crossclamp time was 85 - 19 minutes (range 45 to 140 
minutes) for group A and 109 - 20 minutes (range 74 to 164 minutes) for 
group B (p = 0.02). In 32 patients (86.5%) the aortic homograft was 
implanted as a root with coronary reimplantation. All pulmonary au- 
tografts were implanted as a root. Results: No early or late deaths had 
occurred in this series at a mean follow.up time of 16 months (range 3 to 
21 months). Two patients (one in each group) required reexploration for 
bleeding. No statistically significant differences were observed between the 
two groups with regard to ventilatory support (group A, mean 10 - 8.5 
hours; group B, mean 29 - 85 hours), total blood loss (group A, mean 
471 + 347 ml; group B, mean 543 -+ 404 ml), intensive care unit stay (group 
A, mean 1.2 _ 0.6 days; group B, mean 2 - 3.7 days), and hospital stay 
(group A, mean 9.5 = 3.2 days; group B, mean 12 - 6 days). Postopera- 
tively, all patients are in New York Heart Association class I (93%) or I I  
(7%) (p = not significant). Ejection fraction for the two groups did not 
change significantly over the follow-up period. Left ventricular mass and 
diastolic diameter showed progressive regression, with no apparent differ- 
ence between the two treatment groups to date. Echocardiographic evalu- 
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ation of aortic valve function at 6 months showed good valve function in all 
patients with no evidence of aortic regurgitation in 80% of both groups. In 
group B the right ventricular outflow gradient was below 15 mm Hg over the 
follow-up period. Holter monitoring, available only in 44 patients (63%), 
showed most of the arrhythmias to be grade 0 to 1 of the modified Lown 
grading system. Conclusion: Although the pulmonary autograft requires a 
significantly longer operating time, this does not seem to affect early and 
medium-term outcome when compared with results obtained with aortic 
homografts. Continued patient evaluation is warranted, particularly with 
regard to evidence of valve degeneration and right ventricular function and 
arrhythmias in the long term. (J Thorac Cardiovasc Surg 1997;113: 
894-900) 
U ntreated aortic valve disease leads to ventric- ular hypertrophy or dilatation (or both), an 
adaptive response to pressure or volume over- 
load] Over time, ventricular failure is inevitable, z 
Surgical replacement of the aortic valve interrupts 
this potentially lethal chain of events and has been 
shown to be effective ven in patients in whom the 
risks of surgery are high. 3-6 Both the early and 
long-term results depend to a large degree on the 
type of valve substitute used. The perfect valve 
substitute, however, does not exist. In the search 
for a long-lasting, durable, and nonthrombogenic 
valve, which has the potential of restoring the 
normal hemodynamic profile in the aortic root, 
increased interest has been focused on the aortic 
homograft and the pulmonary autograft. Al- 
though these substitutes were first used clinically 
many years ago, 79 a resurgence of interest in their 
use for replacement of the failing aortic valve has 
recently occurred] 0-15 
The potential clinical and hemodynamic advan- 
tages of both the aortic homograft and pulmonary 
autografl: over conventional mechanical or xenograft 
valve prostheses are now widely recognized. 16' 17 
When compared with homograft aortic valve re- 
placement (AVR), however, the pulmonary au- 
tograft offers even more theoretical advantages, 
such as the potential for growth in children, in- 
creased cellular viability, and enhanced urability 
and possibly internal innervation of the cusps, is 
These potential advantages are balanced, however, 
by the increased complexity and longer duration of 
the operation. Moreover, the potential for coronary 
arterial injury, the effect of the dissection on right 
ventricular function, and the exposure of the patient 
to the disadvantages of two valves at risk are all 
areas of legitimate concern. 
The objective of this study was to prospectively 
compare the effect of AVR with an aortic homograft 
or pulmonary autograft on perioperative variables 
and short- and medium-term clinical performance. 
Patients and methods 
Patient population. From January 1994 to February 
1996, 70 patients, 61 male (87%) and eight female (13%) 
with an age range from 3 to 64 years, were prospectively 
randomized to undergo AVR with an aortic homograft 
(group A, 37 patients; 53%) or a pulmonary autograft 
(group B, 33 patients; 47%). 
Ethical committee approval was obtained before the 
start of the study. Full informed consent was obtained 
from each patient before enrollment. The study was 
designed for patients undergoing isolated AVR regardless 
of their symptomatic status or ventricular function and 
included reoperative procedures, bacterial endocarditis, 
and emergency operations (Table I). Exclusion criteria 
included the need for double valve replacement or coro- 
nary bypass grafting, connective tissue disorders uch as 
Marfan and Ehlers-Danlos syndromes, and autoimmune 
diseases known to affect he aortic valve and root, such as 
active rheumatoid arthritis. Patients who had prior rheu- 
matic carditis were not excluded. 
Eleven patients in the homograft group (28%) and nine 
in the autograft group (27%) had undergone previous 
intracardiac operations (Table I). 
Operative technique and procedures. All operations 
were performed by the same surgeon (M.Y.). Cardiopul- 
monary bypass with moderate hypothermia (30 ° C) was 
used. In both groups myocardial protection was achieved 
by either antegrade crystalloid or cold blood cardioplegia. 
In group A, five patients underwent AVR by the two 
suture line, subcoronary implantation technique. This was 
used when the size and shape of the available homograft 
and the patient's aortic root matched well. All the others 
underwent root replacement with coronary reimplanta- 
tion.19.20 We11 have previously shown that the two tech- 
niques yield comparable results in patients undergoing 
homovital homograft replacement of the aortic valve. In 
group B, the proximal anastomosis was performed with 
interrupted sutures. The right ventricular outflow tract 
was reconstructed with the use of a large homovital or 
antibiotic-sterilized pulmonary homograft conduit in all 
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Table I. Preoperative data 
p 
Variable Homografi Autografi Value 
Patients (No.) 37 (53%) 33 (47%) NS 
Sex (No.) 
Male 34 (92%) 28 (85%) NS 
Female 3 (8%) 5 (15%) NS 
Age (yr) 
Range 12-65 3-54 
Mean _+ SD 39 ± 15 29 _+ 15 
Predominant aortic stenosis (No.) 22 (59%) 19 (58%) NS 
Predominant aortic insufficiency (No.) 10 (27%) 10 (30%) NS 
Combined lesion (No.) 5 (14%) 4 (12%) NS 
Clinical symptoms (No.) 
NYHA I 11 (30%) 9 (27%) NS 
NYHA II 18 (49%) 17 (52%) NS 
NYHA III 8 (21%) 6 (18%) NS 
NYHA IV - -  1 (3%) NS 
Echocardiographic data (mean -- SD) 
EF (%) 65 ± 23 66 _+ 12 NS 
LV mass (gin) 353 _+ 135 418 _+ 181 NS 
Infective ndocarditis (No.) 1 (3%) 3 (9%) NS 
Redo procedure (No.) 11 (30%) 9 (27%) NS 
NS, Not significant; SD, standard eviation; NYHA, New York Heart Association; EF, ejection fraction; LV, left ventricular. 
cases, inserted by continuous 4-0 sutures without inclusion 
of strips of prosthetic or autologous tissue for support. 
These suture lines were performed before release of the 
aortic clamp. In the presence of infective endocarditis, 
aggressive and complete d6bridement of the infected and 
necrotic tissue was performed and no foreign material was 
used for reconstruction. This subgroup of patients re- 
ceived intravenous antibiotics for 6 weeks after the oper- 
ation. 
Cardiopulmonary bypass and aortic crossclamp times 
were 113 -+ 29 and 85 _+ 19 minutes, respectively, for 
group A and 151 _+ 31 (p < 0.002) and 109 _+ 20 minutes, 
respectively (p = 0.02), for group B. Intraoperative trans- 
esophageal echocardiography was used to monitor valve 
and ventricular function before and after insertion of the 
graft. Valve function was judged to be good echocardio- 
graphically in all patients hortly after release of the aortic 
clamp. 
Follow-up. Early mortality was defined as any death 
within 30 days or during initial hospitalization. Postoper- 
ative valve-related morbidity and mortality were evaluated 
and reported according to standard definitions. 21 All 
patients had a clinical examination and a chest roentgen- 
ogram, electrocardiogram, and color-flow Doppler echo- 
cardiogram before discharge, at 6 months, and at yearly 
intervals after that. Blood velocities were calculated at the 
level of the left and right ventricular outflow tracts and at 
the level of the aortic valve orifice, and mean and peak 
gradients were derived by the modified Bernoulli equa- 
tion. Aortic valve insufficiency was graded according to 
the method described by Perry and associates. = Regurgi- 
tation not severe enough to be measured by these criteria 
was considered trivial. Left ventricular mass was derived 
from ventricular dimension. 23 A 24-hour ambulatory elec- 
trocardiographic recording was performed within 6 
months after the operation. 
Statistical analysis. Statistical analysis was performed 
with a commercially available software package (SPSS, 
Inc., Chicago, Ill.). Comparison of demographic and pre- 
operative data between groups was performed with the 
use of an unpaired t test. Comparison of data over time 
was done with the use of a one-way analysis of variance. A
p value of less than 0.05 was accepted as significant. 
Results 
No early or late deaths had occurred at a mean 
follow-up of 16 months (range 3 to 21 months). 
Postoperative complications included reexploration 
for bleeding in two patients, one in each group, and 
a low cardiac output state in a 6-year-old child in the 
autograft group. This patient, who had some fea- 
tures of Shone's disease 24 plus two previous opera- 
tions (mitral commissurotomy and resection of 
subaortic membrane with aortic valvuloplasty), re- 
quired intensive inotropie support and intraaortic 
balloon counterpulsation complicated by lower limb 
ischemia requiring fasciotomy and hemofiltration. 
She was finally extubated on postoperative day 20 
and did well. Other complications included left 
lower lobe atelectasis (n = 3), pneumothorax (n = 
2), and pericardial effusion after implantation of a 
pulmonary autograft (n = 1). No statistically signif- 
icant differences existed between the two groups 
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with regard to ventilatory support (group A, mean 
10 -- 8.5 hours; group B, mean 29 + 85 hours), total 
blood loss (group A, mean 471 + 347 ml; group B, 
mean 543 __ 404 ml), intensive care unit stay (group 
A, mean 1.2 _+ 0.6 days; group B, mean 2 _+ 3.7 
days), and hospital stay (group A, mean 9.5 +_ 3.2 
days; group B, mean 12 _+ 6 days). No significant 
differences were identified between the two groups 
with regard to inotropic support requirements and 
electrocardiographic and biochemical (creatine ki- 
nase MB) evidence of postoperative myocardial 
ischemia.. 
Postoperatively, all patients are either in New 
York Heart Association class I (93%) or II (7%), 
with no significant difference between the two valve 
groups GP = 0.57). No evidence of postoperative 
endocarditis was seen in either group. No patient 
had valve-related complications orevidence of valve 
failure during the follow-up period. The pulmonary 
autograft group had no evidence of root dilatation 
during the short follow-up available. 
Holtcr monitoring. Preliminary analysis of 
Holter monitor data available in 44 patients howed 
no significant difference between the two groups, 
with most of the arrhythmias being grade 0 to 1 of 
the modified Lown grading system. 
Hemodynamic follow-up. Postoperative valua- 
tions of aortic valve gradient, degree of regurgita- 
tion, ejection fraction, left ventricular diameters and 
mass, and right ventricular outflow tract gradient 
were performed at regular intervals. 
Ejection fraction for the two groups did not 
change significantly during the follow-up period. 
Left ventricular diastolic diameter showed a signif- 
icant degree of reduction for each group when 
compared with the preoperative value (analysis of 
variance versus baseline). At discharge, left ventric- 
ular diastolic diameter was reduced by 13% _+ 11% 
and by 16% _+ 12% from the preoperative value in 
the homograft and autograft groups, respectively 
(p = not significant). Postoperative chocardio- 
graphic evaluation of left ventricular mass showed 
evidence of progressive reduction in both groups, 
with no significant difference. Mean and peak gra- 
dients across the aortic valve were calculated in all 
patients. At 1 week, the peak gradient was 6.3 + 3.9 
mm Hg versus 6.7 _+ 3.1 mm Hg for groups A and B, 
respectively. No significant differences were re- 
corded from baseline data over the follow-up time. 
In group B, the right ventricular outflow tract 
gradient at the valve level was consistently less than 
15 mm Hg throughout follow-up. For the same 
period, six patients had a trivial degree of regurgi- 
tation. None of the patients had clinical evidence of 
dysfunction of the right ventricle after the opera- 
tion. 
Discussion 
The present prospective randomized study has 
served to define the influence of the use of the 
pulmonary autograft or AVR on patient outcome, 
clinical status, and left ventricular and valve function 
during the first 2 years. 
Pulmonary autograft implantation is a longer and 
more extensive operation than homograft implanta- 
tion. However, this did not have a significant impact 
on patient survival and postoperative outcome when 
the amount of blood loss and blood product require- 
ment, ventilatory and inotropic support necessary, 
and length of intensive care unit and hospital stay 
were compared between the two patient groups. 
Consequently, hospital costs between the two treat- 
ment groups were judged to be similar. 
Evidence of a comparable amount of blood loss 
and blood product requirement between the two 
groups is of particular interest in view of the more 
extensive dissection required in the harvesting of the 
pulmonary autograft. The exposure of the right 
ventricular outflow tract is an additional potential 
source of bleeding, and delayed pericardial effusion 
(one case in our series) might be related to minor 
vascular and lymphatic leakage from this area. 
In this study we did not exclude patients with poor 
left ventricular function or those requiring emer- 
gency operations, and we have observed no early or 
late deaths at a mean follow-up time of 16 months. 
This result compares favorably with previous tudies 
reporting on the use of different valve substi- 
tutes. 25-2s This could be due to the excellent hemo- 
dynamic performance of the two types of replace- 
ment valves used in this series, particularly in 
patients with active bacterial endocarditis or dimin- 
ished left ventricular function. 
Although the potential for coronary artery injury 
during the Ross operation is widely recognized, 
postoperative monitoring of myocardial ischemia by 
biochemical means (creatine kinase MB) and elec- 
trocardiographic evaluation failed to show a signif- 
icant difference between the two procedures. 
Cardiac function for the two groups, as measured 
by ejection fraction, did not show any significant 
difference in the postoperative period. Postopera- 
tive echocardiographic evaluation of left ventricular 
diameter and mass instead showed a progressive 
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degree of regression in both groups, and this trend is 
maintained over the follow-up period. At discharge, 
the degree of regression of the left ventricular diastolic 
diameter was averaging 14.5% when compared with 
baseline, confirming the impact of the valve substitutes 
used on ventricular hemodynamics and function. The 
postoperative changes of left ventricular mass in the 
two groups over the follow-up period showed relatively 
fast progressive regression of hypertrophy, which was 
similar in the two groups. 
Postoperative echocardiographic evaluation of 
aortic valve function at 6 months revealed no evi- 
dence of aortic regurgitation in more than 80% of 
patients in both groups, with trivial regurgitation in 
less than 15% and mild regurgitation in less than 
6%. This trend appears to be maintained over the 
follow-up period. 
In all patients who had a Ross procedure, the 
gradient across the right ventricular outflow tract 
was below 15 mm Hg. A small percentage of these 
had a trivial degree of regurgitation (18%), indicat- 
ing that the use of a large pulmonary homograft 
conduit for this purpose can give good results, at 
least in the short term. None of the patients in group 
B had evidence of apparent right ventricular dilata- 
tion or dysfunction as viewed by two-dimensional 
echocardiography. 
Postoperatively, all patients are in New York 
Heart Association class I (93%) or II (7%), with no 
significant difference between the two valve groups 
(p = 0.57). No patient had valve-related complica- 
tions or evidence of valve failure during the fol- 
low-up period. 
We conclude that although pulmonary autograft 
implantation is a technically more demanding oper- 
ation than aortic homograft implantation, with a 
longer aortic crossclamp time and cardiopulmonary 
bypass time, both procedures carry a low risk of 
death and equivalent risks of complications. Hospi- 
tal stay and resource utilization appear to be com- 
parable. No clear evidence of ischemic damage was 
found in the two groups. Left and right ventricular 
function appear to be preserved within a medium- 
term follow-up. 
Continued patient evaluation, particularly with 
regard to evidence of valve degeneration and ar- 
rhythmias in the long term, is warranted. 
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Discussion 
Dr. Robert C. Robbins (Stanford, Calif.). This is an 
extremely important paper for those of us who are inter- 
ested in doing the Ross procedure. The objectives of Dr. 
Santini and his associates were satisfactorily achieved in 
that no deaths and no complications, early or late, oc- 
curred in this impressive series. They are also to be 
congratulated on sticking to a prospective randomized 
trial, since this is the first large-scale trial that I am aware 
of that addresses this issue. 
I have a couple of questions pecifically addressing 
the randomization. Were these patients all random- 
ized? They were at two hospitals, the Brompton and 
Harefield, and they w.ere all Mr. Yacoub's patients. Am 
I correct in assuming that all the patients who were 
referred for AVR were randomized regardless of the 
hospitals, or were the patients randomized separately 
between the hospitals? 
Dr. Santini. The patients were randomized inone single 
institution and then were operated On in two different 
institutions. All the patients who came to our attention 
and fulfilled the criteria were randomized; therefore we 
did not randomize those patients who did not consent to 
the randomization. Patients referred to the institution for 
one of the two procedure s received that procedure spe- 
cifically without randomization. 
Dr. Robbins. You noted that there was no statistically 
significant difference between the age of the two groups. 
How were procedures distributed in patients who were 
less than 10 years old (four autografts and no homografts) 
and for those patients older than 50 years old (14 ho- 
mografts and only three autografts). Is that just luck of the 
draw, or did other factors influence this? 
Dr. Santini. The patients had been genuinely random- 
ized, so I think it is just by chance. There was no bias, no 
attempt to perform an autograft in a younger population. 
Because this is an ongoing study, this difference that is 
evident now with 70 patients may be obliterated later on. 
Dr. Robbins. The fact remains that the mean age for the 
patients receiving pulmonary autografts was 10 year s less 
than that of patients receiving homografts, and that could 
have some effect on the study. It will be interesting to see 
how this works out with larger numbers. 
It appears that the first five homografts were implanted 
with a freehand technique and the remainder of the 37 
were done with root replacement with coronary reimplan- 
tation. If this is correct, can you explain why you changed? 
Dr. Santini. We decided after the first few patients to 
adopt the root replacement for both techniques to make 
the two procedures as uniform as possible: I do not think 
the type of procedure used would have an appreciable 
effect, but i n comparing two groups I think it was impor- 
tant to try to adopt the same procedure for both. 
Dr. Robbins. I agree that that would be important. 
What about your technique for doing the autograft? 
You said that you used interrupted running sutures. Does 
that mean that three sutures are placed at the commis- 
sures and run in between? 
Dr. Santini. That was for the distal suture line. For the 
proximal suture lines we have always used interrupted 4-0 
Ethibond sutures (Ethicon, Inc., Somerville, N.J.). The 
distal suture line has been done with Prolene sutures 
(Ethicon) interrupted three times. 
Dr. Rohbins. I see. You use a homograft for root 
replacement, and when a pulmonary translocation is
performed the proximal sutures are interrupted. 
Dr. Santini. Yes. 
Dr. Robbins. When you are reconstructing the right 
ventricular outflow tract, is the clamp on or off? How does 
that affect the erossclamp time? 
Dr. Santini. Both the distal and proximal anastomoses 
have been done with the crossclamp off. 
Dr. Robbins. Were the patients who received the 
autografts receiving continuous retrograde cardioplegia? 
Was there any difference between the two groups in how 
the cardioplegic solution was given? 
Dr. Santini. I think the numbers in this cohort of 
patients are too small to identify any statistically signifi- 
cant difference. When the groups have more patients, 
approaching 100 or 200, it might be easier to make that 
assessment. 
Dr. Robbins. Did the transesophageal chocardiogram 
change anything that you did during the operation? Were 
there ever any cases in which you went back and changed 
the way that the grafts were implanted because of exces- 
sive regurgitation? 
Dr. Santini. No. Transesophageal echocardiography 
has been used at the very beginning of the procedure to 
assess the incompetence of the pulmonary valve, particu- 
larly for the autograft group, and then off bypass to 
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evaluate the competence of the aortic root and the aortic 
valve, but in no case have we had to go back on bypass to 
modify the operation. 
Dr. Robbins. I hope you will continue to randomize 
patients, and I hope you will come back in 15 to 20 years 
to answer this question: Is it worth the time and the effort 
to put the patients through a more complex operation 
because of less valve deterioration with the pulmonary 
autograft? 
Dr. John P. McDermott (Redding, Calif.). In the past 
4 years, 75% of our patients who have received AVR have 
been more than 75 years old. The mean ages for your 
populations for the homograft and pulmonary translocations 
have been in the 30- to 35-year-old range. Do you have an 
opinion about a cutoff in terms of age or other noncardiac 
medical issues that would affect your decision to do the 
pulmonary translocation? In what types of older patients 
have you done this procedure? 
Second, would you expect he longer cardiopulmonary 
bypass times to cause more complications in the older 
patients than in the younger age group? 
Dr. Santini. In the inclusion criteria, the oldest 
patient in whom we decided to perform this operation 
was 60 years old, but then we decided to base this 
decision on a biological age rather than a chronological 
age. We therefore performed either of the two proce- 
dures whenever we were expecting at least 15 years of 
survival. On the basis of our experience, I think this 
should be the criterion. For older patients, I would not 
embark on a procedure that is definitely longer, partic- 
ularly because these older patients may have additional 
clinical conditions that contraindicate a longer bypass 
time than is necessary with a more conventional AVR, 
whatever the prosthetic device. 
Dr. McDermott. Am I correct hat your oldest patient in 
the translocation group was 60 years old? 
Dr. Santini. On the basis of this study, I think the 
autograft can be offered to patients 60 years old. 
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